Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy. However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in HCC and overcomes chemotherapy resistance in other settings. We studied the efficacy of combining the anti-EGFR antibody cetuxi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sanoff, Hanna K., Bernard, Stephen, Goldberg, Richard M., Morse, Michael A., Garcia, Reynaldo, Woods, Lynna, Moore, Dominic T., O'Neil, Bert H.
Médium: Artigo
Jazyk:Inglês
Vydáno: International Society of Gastrointestinal Oncology 2011
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3201640/
https://ncbi.nlm.nih.gov/pubmed/22043322
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky